3-amino-2-hydroxy-N,N-dimethylpropanamide | 1300100-58-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-2-hydroxy-N,N-dimethylpropanamide
• CAS: 1300100-58-6
• 化学式: C₅H₁₂N₂O₂
• 分子量: 132.162
• InChiKey: ZGPXXBMXRVWPNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-amino-2-hydroxy-N,N-dimethylpropanamide 在 重铬酸吡啶 、 三乙胺 、 三氟乙酸 、 mercury dichloride 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 (6S,9R)-6-(2,3-difluorophenyl)-N,N-dimethyl-9-(4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamido)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine-3-carboxamide
  参考文献：
  名称：

  Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

  摘要：

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.054
• 作为产物：
  描述：

  tert-butyl (3-(dimethylamino)-2-hydroxy-3-oxopropyl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-amino-2-hydroxy-N,N-dimethylpropanamide
  参考文献：
  名称：

  3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS

  摘要：

  本公开涉及抑制锌依赖性组蛋白去乙酰化酶（HDACs）的抑制剂，用于治疗与HDAC（例如HDAC6）相关的疾病或疾病，其具有以下式I： 其中R、L、X1、X2、X3、X4、Y1、Y2、Y3和Y4如本文所述。

  公开号：

  US20160222028A1

文献信息

• 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
  申请人：Forma Therapeutics, Inc.

  公开号：US20160222028A1

  公开（公告）日：2016-08-04

  The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X 1 , X 2 , X 3 , X 4 , Y 1 , Y 2 , Y 3 , and Y 4 are described herein.

  本公开涉及抑制锌依赖性组蛋白去乙酰化酶（HDACs）的抑制剂，用于治疗与HDAC（例如HDAC6）相关的疾病或疾病，其具有以下式I： 其中R、L、X1、X2、X3、X4、Y1、Y2、Y3和Y4如本文所述。
• Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918
  作者：Daniel V. Paone、Diem N. Nguyen、Anthony W. Shaw、Christopher S. Burgey、Craig M. Potteiger、James Z. Deng、Scott D. Mosser、Christopher A. Salvatore、Sean Yu、Shane Roller、Stefanie A. Kane、Harold G. Selnick、Joseph P. Vacca、Theresa M. Williams

  DOI：10.1016/j.bmcl.2010.12.054

  日期：2011.5

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.